Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

Abstract

MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of -(1,3)- glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s). Copyright © 2014, American Society for Microbiology. All Rights Reserved.